专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2005076012A3 NOVEL SPLICE VARIANTS AND METHODS OF USE THEREOF 审中-公开
标题翻译：新的差距变量及其使用方法
公开(公告)号：WO2005076012A3
公开(公告)日：2006-02-16
申请号：PCT/US2005002695
申请日：2005-01-31
申请人： FIVE PRIME THERAPEUTICS INC , CHU KETING , COLLINS AMY L TSUI , LEE ERNESTINE , WONG JUSTIN G P
发明人： CHU KETING , COLLINS AMY L TSUI , LEE ERNESTINE , WONG JUSTIN G P
IPC分类号： C07K14/47 , C07K16/40 , G01N33/50 , G01N33/566 , G01N33/574 , G01N33/68
CPC分类号： G01N33/5011 , C07K14/47 , C07K16/40 , G01N33/566 , G01N33/574
摘要： The present invention relates to splice variants of polypeptides that are highly expressed in tumor tissues. Such polypeptides are useful for therapeutic, diagnostic, and prophylactic purposes. In particular, the polypeptides herein are useful as targets for development of modulators for treatment of diseases.
摘要翻译：本发明涉及在肿瘤组织中高度表达的多肽的剪接变体。这样的多肽可用于治疗，诊断和预防目的。特别地，本文的多肽可用作开发用于治疗疾病的调节剂的靶标。

22. 发明申请

WO0228481A2 METHODS OF THERAPY FOR B-CELL MALIGNANCIES 审中-公开
标题翻译： B细胞恶性肿瘤的治疗方法
公开(公告)号：WO0228481A2
公开(公告)日：2002-04-11
申请号：PCT/US0130963
申请日：2001-10-02
申请人： CHIRON CORP , CHU KETING , MASUOKA LORIANNE
发明人： CHU KETING , MASUOKA LORIANNE
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N15/13 , C12P21/08
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译：提供了B细胞恶性肿瘤的治疗方法。该方法包括向有需要的患者施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段。拮抗性抗CD40抗体或其抗原结合片段是免费显著激动活性时，抗体结合上的正常人B细胞中的CD40抗原，当抗体结合于恶性人B细胞中的CD40抗原表现出拮抗剂活性，并且当抗体结合正常人B细胞上的CD40抗原时可以表现出拮抗剂活性。抗CD40抗体或其抗原结合片段的拮抗剂活性有益地抑制恶性人B细胞的增殖和/或分化。

23. 发明申请

WO0228480A3 METHODS OF THERAPY FOR B-CELL MALIGNANCIES 审中-公开
标题翻译： B细胞恶性肿瘤治疗方法
公开(公告)号：WO0228480A3
公开(公告)日：2002-07-11
申请号：PCT/US0130961
申请日：2001-10-02
申请人： CHIRON CORP , CHU KETING , MASUOKA LORIANNE
发明人： CHU KETING , MASUOKA LORIANNE
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N15/13 , C12P21/08
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译：提供了B细胞恶性肿瘤治疗方法。所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。当抗体结合正常人B细胞上的CD40抗原时，拮抗性抗-CD40抗体或其抗原结合片段没有明显的激动剂活性，当抗体结合恶性人B细胞上的CD40抗原时，拮抗剂抗CD40抗体或其抗原结合片段，当抗体结合正常人B细胞上的CD40抗原时，可以显示拮抗剂活性。抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制恶性人B细胞的增殖和/或分化。

24. 发明申请

WO0228481A9 METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES 审中-公开
标题翻译：使用拮抗剂抗CD40抗体治疗B细胞恶性肿瘤的方法
公开(公告)号：WO0228481A9
公开(公告)日：2003-07-03
申请号：PCT/US0130963
申请日：2001-10-02
申请人： CHIRON CORP , CHU KETING , MASUOKA LORIANNE
发明人： CHU KETING , MASUOKA LORIANNE
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N15/13 , C12P21/08
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译：提供了B细胞恶性肿瘤治疗方法。所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。当抗体结合正常人B细胞上的CD40抗原时，拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，当抗体结合恶性人B细胞上的CD40抗原时，拮抗剂抗CD40抗体或其抗原结合片段，当抗体结合正常人B细胞上的CD40抗原时，可以显示拮抗剂活性。抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制恶性人B细胞的增殖和/或分化。

25. 发明申请

WO2008151146A3 PEPTIDE ARRAYS AND METHODS OF USE 审中-公开
标题翻译：肽类阵列和使用方法
公开(公告)号：WO2008151146A3
公开(公告)日：2009-02-26
申请号：PCT/US2008065559
申请日：2008-06-02
申请人： DIGITAB INC , CHU KETING
发明人： CHU KETING
IPC分类号： G01N33/68
CPC分类号： G01N33/6845 , C07K1/047
摘要： Peptide arrays and uses thereof for diagnostics, therapeutics and research. Ultra high density peptide arrays are generated using photolithography, such as using photoresist techniques.
摘要翻译：肽阵列及其用途，用于诊断，治疗和研究。使用光刻法生产超高密度肽阵列，例如使用光致抗蚀剂技术。

26. 发明申请

WO2009079308A2 COMPOSITION AND METHOD OF USE OF SHEEP FAB PHAGE DISPLAY LIBRARY 审中-公开
标题翻译：羊FAB显示文库的组成和使用方法
公开(公告)号：WO2009079308A2
公开(公告)日：2009-06-25
申请号：PCT/US2008086289
申请日：2008-12-10
申请人： DIGITAB INC , CHU KETING , YANG RANDY , WANG JIANFU JEFFREY
发明人： CHU KETING , YANG RANDY , WANG JIANFU JEFFREY
IPC分类号： C07K16/18 , C12N7/01 , C12N15/10
CPC分类号： C07K16/005 , C07K16/18 , C07K2317/21 , C07K2317/55 , C12N15/1037
摘要： The present invention discloses methods of producing sheep monoclonal antibodies by expanding mRNA. One method involves the construction of sheep monoclonal Fab antibodies by phage display. The present invention also discloses antibodies produced by the methods disclosed herein. Other methods of the present invention involve using the antibodies produced by the methods of the present invention to treat patients, perform diagnostic procedures, and/or conduct research.
摘要翻译：本发明公开了通过扩增mRNA产生绵羊单克隆抗体的方法。一种方法涉及通过噬菌体展示构建绵羊单克隆Fab抗体。本发明还公开了通过本文公开的方法产生的抗体。本发明的其他方法涉及使用通过本发明的方法产生的抗体来治疗患者，执行诊断程序和/或进行研究。

27. 发明申请

WO0228904A3 HUMAN ANTI-CD40 ANTIBODIES 审中-公开
公开(公告)号：WO0228904A3
公开(公告)日：2003-02-06
申请号：PCT/US0130857
申请日：2001-10-02
申请人： CHIRON CORP , CHU KETING , WANG CHANGYU , YOSHIHARA CORRINE , DONNELLY JOHN J
发明人： CHU KETING , WANG CHANGYU , YOSHIHARA CORRINE , DONNELLY JOHN J
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N15/13 , C12P21/08
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Human antibodies capable of binding CD40 are disclosed, wherein the antibodies act as antagonists of CD40-directed activities of B cells, but have no or minimal ability to induce B cell proliferation. The antibodies are useful for treating diseases mediated by CD40-expressing cells, such as those diseases characterized by B cell activation, as well as cancer of B-cell lineage, including Non-Hodgkin's Lymphoma.

28. 发明申请

WO0038706A9 METHODS FOR TREATING CANCER AND FOR MEDIATING CHEMOTAXIS OF DENDRITIC CELLS 审中-公开
标题翻译：用于治疗癌症和介导感染细胞化学的方法
公开(公告)号：WO0038706A9
公开(公告)日：2002-08-22
申请号：PCT/US9931096
申请日：1999-12-28
申请人： CHIRON CORP , CHU KETING , XIN HONG , CHAN VIVIEN W F , KOTHAKOTA SRINIVAS , WILLIAMS LEWIS T , WINTER JILL A
发明人： CHU KETING , XIN HONG , CHAN VIVIEN W F , KOTHAKOTA SRINIVAS , WILLIAMS LEWIS T , WINTER JILL A
IPC分类号： C12N15/02 , A61K31/711 , A61K38/00 , A61K38/19 , A61K38/20 , A61K39/395 , A61K45/00 , A61K48/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07K14/47
CPC分类号： A61K38/195 , A61K38/2013 , A61K2300/00
摘要： The invention is based on the novel observation, reported herein, that SLC inhibits the growth of tumors in vivo and is a potent chemokine for Dendritic Cells (DC). Thus, the invention provides a method of treating cancer or hyperproliferative disorder in a mammalian subject, comprising: administering a therapeutically effective amount of an SLC to said subject. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids. The methods of the invention are useful in the treatment of cancer and hyperproliferative disorders. In addition, the invention provides methods for modulating dendritic cell function in a mammal, said method comprising administering a therapeutically effective amount of an SLC agent to said mammal, said agent selected from the group consisting of: SLC plypeptides, SLC polypeptide variants, SLC polypeptide fragments, polynucleotides encoding SLC polypeptides, variants and fragments, anti-SLC antibodies and ligands for the CCR7 receptor. Such methods can be used to increase or decrease an immune response, particularly a primary immune response, in a mammal. The methods are particularly useful in the prevention of graft rejection and in the treatment of autoimmune disease. Alternatively, the methods may be used to enhance an immune response.
摘要翻译：本发明基于本文报道的新观察，SLC抑制体内肿瘤的生长，并且是树突状细胞（DC）的有效趋化因子。因此，本发明提供了在哺乳动物受试者中治疗癌症或过度增殖性疾病的方法，其包括：向所述受试者施用治疗有效量的SLC。可用于本发明方法的SLC包括SLC多肽，变体和片段及相关核酸。本发明的方法可用于治疗癌症和过度增殖性疾病。另外，本发明提供调节哺乳动物树突状细胞功能的方法，所述方法包括向所述哺乳动物施用治疗有效量的SLC剂，所述药物选自：SLC多肽，SLC多肽变体，SLC多肽片段，编码SLC多肽的多核苷酸，变体和片段，抗SLC抗体和CCR7受体的配体。这样的方法可用于增加或减少哺乳动物的免疫应答，特别是初级免疫应答。该方法特别可用于预防移植物排斥和治疗自身免疫性疾病。或者，所述方法可用于增强免疫应答。

29. 发明申请

WO0228905A3 HUMAN ANTI-CD40 ANTIBODIES 审中-公开
标题翻译：人类抗CD40抗体
公开(公告)号：WO0228905A3
公开(公告)日：2002-06-20
申请号：PCT/US0130859
申请日：2001-10-02
申请人： CHIRON CORP , CHU KETING , WANG CHANGYU , YOSHIHARA CORRINE , DONNELLY JOHN J
发明人： CHU KETING , WANG CHANGYU , YOSHIHARA CORRINE , DONNELLY JOHN J
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N15/13 , C12P21/08 , C12N5/20
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Human antibodies capable of binding CD40 are disclosed, wherein the antibodies act as antagonists of CD40-directed activities of B cells, but have no or minimal ability to induce B cell proliferation. The antibodies are useful for treating diseases mediated by CD40-expressing cells, such as those diseases characterized by B cell activation, as well as cancer of B-cell lineage, including Non-Hodgkin's Lymphoma.
摘要翻译：公开了能够结合CD40的人抗体，其中所述抗体充当B细胞的CD40-定向活性的拮抗剂，但是没有或具有最小的诱导B细胞增殖的能力。这些抗体可用于治疗表达CD40的细胞（例如以B细胞活化为特征的疾病）以及B细胞谱系癌（包括非霍奇金淋巴瘤）介导的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式